Analysis of Revenues
Paying user area
Try for free
Celgene Corp. pages available for free this week:
- Statement of Comprehensive Income
- Balance Sheet: Assets
- Analysis of Long-term (Investment) Activity Ratios
- Enterprise Value (EV)
- Price to FCFE (P/FCFE)
- Capital Asset Pricing Model (CAPM)
- Dividend Discount Model (DDM)
- Return on Equity (ROE) since 2005
- Total Asset Turnover since 2005
- Aggregate Accruals
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Celgene Corp. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Revenues as Reported
Celgene Corp., income statement, revenues
US$ in millions
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).
The revenue data over the five-year period demonstrates distinct growth trends across multiple product lines with some exceptions, indicating shifts in market performance and product life cycles.
- REVLIMID®
- The revenue from REVLIMID® shows a consistent and significant upward trend, increasing from $4,980 million in 2014 to $9,685 million in 2018. This nearly doubles the revenue over five years, indicating strong demand and successful market penetration or pricing strategies.
- POMALYST®/IMNOVID®
- Revenues from POMALYST®/IMNOVID® also exhibit robust growth, rising steadily from $680 million in 2014 to $2,040 million in 2018. This represents approximately a threefold increase over the period, suggesting expanding usage or acceptance in its therapeutic area.
- OTEZLA®
- OTEZLA® displays the most rapid relative revenue growth, starting at $70 million in 2014 and rising sharply to $1,608 million by 2018. This strong upward trajectory reflects rapid market adoption and significant contribution to overall sales by the end of the period.
- ABRAXANE®
- The ABRAXANE® product line shows relatively stable revenues with minor increases, moving from $848 million in 2014 to $1,062 million in 2018. This slower growth compared to other products suggests a mature market position with steady but limited expansion.
- IDHIFA®
- IDHIFA® revenue appears only in the last two years, beginning at $20 million in 2017 and rising to $72 million in 2018. This indicates a new product launch and early-stage revenue growth, which could suggest potential for future contribution.
- VIDAZA®
- VIDAZA® revenues are relatively flat to slightly declining, with $612 million in 2014 reducing marginally to $594 million in 2018. This suggests product maturity with stable but not growing sales.
- Azacitidine for injection
- Revenues from Azacitidine for injection show a clear declining trend, decreasing from $78 million in 2014 to $23 million in 2018. This decline indicates either reduced market demand or replacement by alternative therapies.
- THALOMID®
- THALOMID® revenue declines steadily from $221 million in 2014 to $114 million in 2018, reflecting a likely product lifecycle downturn or decreasing market relevance over the period.
- ISTODAX®
- ISTODAX® revenue remains relatively constant with minor fluctuations, recording $66 million in 2014 and $63 million in 2018, suggesting stable but limited demand.
- Other
- The 'Other' category exhibits very low revenues with no clear trend, fluctuating between $4 million and $9 million, and thus contributes minimally to the overall revenue profile.
- Net product sales
- Total net product sales show a strong upward trend, growing from $7,564 million in 2014 to $15,265 million in 2018, effectively doubling over five years. This overall increase is primarily driven by strong growth in REVLIMID®, POMALYST®/IMNOVID®, and OTEZLA® revenues, which offset declining revenues in older products such as THALOMID® and Azacitidine for injection.